Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RSKet: Imaging Neural Correlates of Ketamine Stereoisomers
NCT04587778Phase 1Recruiting
- Sponsor
- Medical University of Vienna
- Start
- Oct 2020
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of esketamine and ketamine in major depressive disorder (MDD) (3 arms), sponsored by Medical University of Vienna. Primary endpoints: Change in Cerebral Metabolic Rate of Glucose and Change in Cerebral Blood Flow. Started Oct 2020; status: recruiting.
02
Drugs
esketamineketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT04587778.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04587778.